P. Chène
Molecular Biology · 2003–2008
A researcher in the Science corpus: 2 papers; trusts 1 researcher and is trusted by 4 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 26 citations into it; #9,370 of 17,773 by trust here, #10,047 by citations
Whom P. Chène trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts P. Chène overall
Papers from P. Chène's perspective
Ordered by how strongly the researchers P. Chène trusts endorse each paper. Same corpus, a different order for every researcher.
- Cancer genes and the pathways they control (Nature Medicine)
- High Frequency of Mutations of the PIK3CA Gene in Human Cancers (Science)
- Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR (Proceedings of the National Academy of Sciences of the United States of America)
- mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. (Cancer Research)
- Ras, PI(3)K and mTOR signalling controls tumour cell growth (Nature)
- The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism (Nature reviews genetics)
- Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. (Developmental Cell)
- Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis (Nature Reviews. Cancer)
- Principles of protein-protein interactions (European Conference on Computational Biology)
- Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling (Proceedings of the National Academy of Sciences of the United States of America)
Their papers
- Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity (2008) — 1,165 citations
- Inhibiting the p53–MDM2 interaction: an important target for cancer therapy (2003) — 723 citations